Instil Bio (TIL)
(Delayed Data from NSDQ)
$31.77 USD
-2.51 (-7.32%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $31.85 +0.08 (0.25%) 7:30 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.77 USD
-2.51 (-7.32%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $31.85 +0.08 (0.25%) 7:30 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Zacks News
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?
by Zacks Equity Research
Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
by Zacks Equity Research
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
by Zacks Equity Research
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
What Makes Instil Bio (TIL) a New Buy Stock
by Zacks Equity Research
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why
by Zacks Equity Research
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)
by Zacks Equity Research
Instil Bio, Inc. (TIL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down 59.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)
by Zacks Equity Research
Instil Bio, Inc. (TIL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Company News for Mar 8, 2022
by Zacks Equity Research
Companies in The News Are: VET,AMR,TIL,BBBY,GME